We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Corbus (CRBP) This Earnings Season?
Read MoreHide Full Article
Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) is scheduled to release first-quarter 2019 results on May 9, 2019.
In the last reported quarter, the company incurred loss that was wider than the Zacks Consensus Estimate. Moreover, Corbus missed earnings estimates in the trailing four quarters, the average negative earnings surprise being 56.92%.
Let’s see how things are shaping up prior to the announcement of the upcoming first-quarter 2019 results.
Factors Likely to Impact Q1 Results
Corbus is a clinical-stage drug development company, focused on treating inflammatory and fibrotic diseases through the endocannabinoid system (“ECS”) pathways.
The company’s lead product, lenabasum, is a novel synthetic, oral, endocannabinoid drug designed to resolve chronic inflammation and fibrotic processes. The candidate is being developed to treat four life-threatening diseases — systemic sclerosis (SSc), cystic fibrosis (CF), dermatomyositis (DM) and systemic lupus erythematosus (SLE).
Corbus completed enrollment in the phase III RESOLVE-1 study of lenabasum on SSc in May 2019 and expects to report top-line results in 2020.
Enrollment and dosing are ongoing in a phase IIb study of lenabasum for the treatment of CF and the company expects to report top-line data from the study in 2020.
In December 2018, it initiated the phase III DETERMINE study to evaluate the efficacy and safety of lenabasum for the treatment of DM. We expect more updates on this study in the first-quarter conference call.
The company is also enrolling and dosing patients in a phase II study of lenabasum for the treatment of SLE
It should provide updates on these studies of lenabasum in the first quarter of 2019.
Apart from these studies, investors’ focus will be on other pipeline updates when Corbus reports first-quarter 2019 results.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for Corbus in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Corbus has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Corbus Pharmaceuticals Holdings, Inc. Price and EPS Surprise
Zacks Rank: The company currently has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Inovio Pharmaceuticals, Inc. (INO - Free Report) is scheduled to report first-quarter 2019 results on May 9. The company has an Earnings ESP of +13.79% and a Zacks Rank of 3.
Genmab A/S (GNMSF - Free Report) is scheduled to report first-quarter 2019 results on May 8. The company has an Earnings ESP of +80.95% and a Zacks Rank of 1.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Image: Bigstock
What's in the Cards for Corbus (CRBP) This Earnings Season?
Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) is scheduled to release first-quarter 2019 results on May 9, 2019.
In the last reported quarter, the company incurred loss that was wider than the Zacks Consensus Estimate. Moreover, Corbus missed earnings estimates in the trailing four quarters, the average negative earnings surprise being 56.92%.
Let’s see how things are shaping up prior to the announcement of the upcoming first-quarter 2019 results.
Factors Likely to Impact Q1 Results
Corbus is a clinical-stage drug development company, focused on treating inflammatory and fibrotic diseases through the endocannabinoid system (“ECS”) pathways.
The company’s lead product, lenabasum, is a novel synthetic, oral, endocannabinoid drug designed to resolve chronic inflammation and fibrotic processes. The candidate is being developed to treat four life-threatening diseases — systemic sclerosis (SSc), cystic fibrosis (CF), dermatomyositis (DM) and systemic lupus erythematosus (SLE).
Corbus completed enrollment in the phase III RESOLVE-1 study of lenabasum on SSc in May 2019 and expects to report top-line results in 2020.
Enrollment and dosing are ongoing in a phase IIb study of lenabasum for the treatment of CF and the company expects to report top-line data from the study in 2020.
In December 2018, it initiated the phase III DETERMINE study to evaluate the efficacy and safety of lenabasum for the treatment of DM. We expect more updates on this study in the first-quarter conference call.
The company is also enrolling and dosing patients in a phase II study of lenabasum for the treatment of SLE
It should provide updates on these studies of lenabasum in the first quarter of 2019.
Apart from these studies, investors’ focus will be on other pipeline updates when Corbus reports first-quarter 2019 results.
What Does the Zacks Model Unveil?
Our proven model does not conclusively show an earnings beat for Corbus in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Corbus has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Corbus Pharmaceuticals Holdings, Inc. Price and EPS Surprise
Corbus Pharmaceuticals Holdings, Inc. Price and EPS Surprise | Corbus Pharmaceuticals Holdings, Inc. Quote
Zacks Rank: The company currently has a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Horizon Pharma plc is scheduled to report first-quarter 2019 results on May 8. The company has an Earnings ESP of +25.00% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Inovio Pharmaceuticals, Inc. (INO - Free Report) is scheduled to report first-quarter 2019 results on May 9. The company has an Earnings ESP of +13.79% and a Zacks Rank of 3.
Genmab A/S (GNMSF - Free Report) is scheduled to report first-quarter 2019 results on May 8. The company has an Earnings ESP of +80.95% and a Zacks Rank of 1.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>